Mucosal immunization of mice with purified BordeteUla pertussis filamentous hemagglutinin (FHA), by either the respiratory or the gut route, was found to protect against B. pertussis infection of the trachea and lungs.
Pertussis is a highly contagious human respiratory disease, typified by episodes of paroxysmal coughing, that is caused by the gram-negative bacillus Bordetella pertussis. B. pertussis infects via inhalation of aerosol droplets and preferentially associates with the cilia of the respiratory epithelium lining the nasopharynx, trachea, and bronchial tree. During the course of disease, B. pertussis infection remains localized to the respiratory tract and does not progress to bacteremia or meningitis (4, 6) .
The localization of B. pertussis infection to the ciliated epithelium of the respiratory tract suggests that adherence of this bacterium to cilia is a critical step in B. pertussis pathogenesis. Filamentous hemagglutinin (FHA) is a 220-kDa filamentous protein that is proposed to be one of the major adhesins mediating the interaction of B. pertussis and human cilia (17, 31) .
While parenteral vaccination with either whole-cell (2) or a two-component acellular pertussis vaccine (1) has been effective in protection against clinical disease, there is, to date, no correlation between serum antibody titers to known purified pertussis antigens and clinical protection (1, 2) . Therefore, aspects of immunity other than serum antibody may better reflect pertussis prophylaxis.
After natural B. pertussis infection, high titers of immunoglobulin A (IgA) antibodies to FHA have been detected in the nasal secretions of convalescent patients (20, 40) . Naturally occurring B. pertussis infection has been shown to confer long-lasting protection against reinfection, while parenteral vaccination induces protection that wanes in young adulthood (18) . Long-lived resistance to pertussis, therefore, may reflect the induction of persistent mucosal immunity which can be recalled at the respiratory mucosa upon subsequent infection.
After experimental respiratory infection of mice with B. pertussis, the bacterium has been demonstrated to be asso-* Corresponding author. ciated with the ciliated epithelium of the murine trachea (35) and bronchial tree (33) . Therefore, respiratory infection of mice may be used to analyze parameters of immunity that interfere with the persistence of B. pertussis at the respiratory epithelium. The purpose of this study was to determine the ability of mucosal immunization with FHA to stimulate an antigen-specific immune response in the respiratory tract that could protect against B. pertussis infection.
MATERIALS AND METHODS
Mice. BALB/cAnNcR or (C57/B16 x C3H/HeN)F1 adult mice (B6C3 mice), 5 to 8 weeks of age, and BALB/cAnNcR newborn mice were obtained from the Animal Production Program, Division of Cancer Treatment, National Cancer Institute, Frederick, Md. Mice were maintained in microisolators under specific-pathogen-free conditions. Antigens. FHA, purified from B. pertussis Tohama I, was kindly provided by Alan Kimura and James Cowell, Praxis Biologics, Rochester, N.Y., and by Jean Petre and Carine Capiau, Smith Kline Biologicals, Rixensart, Belgium. The preparations of FHA used in these studies ran predominantly as single bands of 220 kDa on sodium dodecyl sulfate (SDS)-polyacrylamide gels, had less than 0.005% pertussis toxin contamination, and contained approximately 0.05% endotoxin (17) or were purified from a strain from which the pertussis toxin gene had been deleted and which contained approximately 0.0006% endotoxin (Smith Kline preparation) as determined by the Limulus amoebocyte lysate assay. Both preparations yielded similar results in these studies.
Intranasal immunization. Antigen in sterile saline (50 ,ul) was deposited on the nares of mice that had been anesthetized with Metofane inhalant anesthesia (Pitman Moore, Chicago, Ill.), and the mice were held upright until the antigen had been inhaled. As a control for cross-contamination of the gastrointestinal tract during intranasal inoculation, mice were administered Evans blue dye (Sigma Chemical Co., St. Louis, Mo.) under the conditions described above. Examination of the respiratory tracts and gastrointestinal tracts of these animals showed that the dye remained localized to the trachea, bifurcation of the bronchi, and upper portions of the lungs; no dye was observed in the esophagus, stomach, or duodenum.
Intraduodenal immunization. Mice were anesthetized intraperitoneally with 0.35 ml of a 2% solution of 2,2,2-tribromoethanol (Aldrich Chemical Co., Milwaukee, Wis.). A midline incision below the sternum was made, and 0.2 ml of antigen in sterile saline was injected into the lumen of the duodenum by using a 30-gauge needle (Becton Dickinson and Co., Rutherford, N.J.) as previously described (15) . The injection site was inspected to ensure that there was no leakage, and the incisions were sutured.
Aerosol challenge. A 21-h culture of B. pertussis 18323 grown on Bordet-Gengou agar was suspended in sterile phosphate-buffered saline (PBS) at a concentration of approximately 109 CFU/ml of inoculum. The challenge inoculum was administered to mice as an aerosol for 30 min as previously described (37) . Mice were removed from the chamber 1 h after termination of the aerosol challenge, at which point viable B. pertussis cannot be cultured from the surface of the animals or the chamber. Two Immunoblot analysis was used to demonstrate the specificity of antibodies elicited by immunization with the preparations of FHA described above. Tricine urea extracts of B. pertussis 18323 (12) were analyzed electrophoretically on an SDS-polyacrylamide gel with a 4 to 20% polyacrylamide gradient (Integrated Separation Systems, Hyde Park, Mass.) and transferred to nitrocellulose. Strips of the nitrocellulose were incubated with either a mixture of the monoclonal antibodies MO8X3C and 12.1D3 as a positive control for FHA or serum or BAL fluid from mice immunized intranasally with FHA, and they were then developed with alkaline phosphatase-conjugated goat anti-mouse Ig as previously described (37) . MO8X3C recognizes the same proteolytic fragments of FHA as does MO8X3E (37) and was a gift from J. Kenimer, U.S. Food and Drug Administration. 12.1D3 recognizes proteolytic fragments of FHA not seen by MO8X3C (8) and was generously provided by C. Locht, Institut Pasteur, Lille, France.
Total IgG and IgA titers were determined by incubating plates coated with 5 ,ug of unlabelled goat anti-mouse Ig (Southern Biotechnology Associates) per ml with dilutions of BAL fluid or nasal wash for 3 h. After being washed the plates were incubated with alkaline phosphatase-conjugated goat anti-mouse IgG or IgA and developed as described above. Anti-FHA titers as well as total Ig titers are expressed as the reciprocal of the endpoint dilution, calculated by extrapolation to zero from the linear part of the titration curve.
Limiting dilution analysis. Lymphocytes were isolated from the lungs of B6C3 mice by mild enzymatic treatment (34) or from the spleens of mice by mechanical dispersion and were analyzed in limiting dilution microcultures (in the absence of dendritic cells) as previously described (36) . Supernatants were collected after 7 days of culture and analyzed by ELISA for the production of anti-FHA antibodies. The percentage of B lymphocytes in each preparation was determined by staining with fluorescein-conjugated goat anti-mouse total Ig (Southern Biotechnology Associates).
Frequencies of FHA-specific B cells were calculated by Poisson analysis. RESULTS Time course of bacterial recovery. The initial bacterial recovery from the lungs of unimmunized, aerosol-infected adult mice, determined 1 h after aerosol challenge, was 105 CFU of B. pertussis (Fig. 1 ). An increase in bacterial recovery, to 107 CFU, was observed 1 week postinfection and declined thereafter (Fig. 1) . Therefore, protection, measured by comparing the bacterial recovery from the lungs of immunized mice with that of unimmunized mice, was determined in the reported experiments at 1 week postinfection.
Parenteral tory tract. Adult BALB/c mice immunized with two intranasal doses of 100 ,ug of FHA, given 1 week apart, and challenged 3 weeks after the last immunization, had a 2 to 3 log reduction (P < 0.01) in bacterial recovery from their lungs, as well as a 1 to 2 log reduction (P < 0.01) in bacterial recovery from their tracheas, in comparison to the bacterial recoveries from the lungs of unimmunized, infected control mice (Table 1) .
B6C3 mice, used in limiting dilution experiments, were also analyzed. Immunized B6C3 mice had a 3 log reduction (P < 0.01) in bacterial recovery from their lungs and a 2 log reduction (P < 0.01) in bacterial recovery from their tracheas in comparison to those recoveries in unimmunized controls (Table 1 ). In the experiments described in Table 1 , 25 and 63% of the mice in immunized groups 1 and 2, respectively, completely cleared the infection from their tracheas.
Analysis of the sera and BAL fluid collected from intranasally immunized mice on the day of aerosol challenge revealed detectable titers of anti-FHA antibodies that increased 1 week after aerosol challenge ( (Fig. 2) .
Since the concentration of specific antibody in the BAL fluid can be affected by variations in fluid recovery during lavage, we attempted to normalize the concentration of specific IgG and IgA anti-FHA antibody to the concentration of total IgG and total IgA in the BAL fluid. However, quantitation of total antibody in BAL fluids at different times after aerosol challenge revealed an increase in both total IgG as well as total IgA in unimmunized, aerosol infected mice (Table 3 ). However, little or no increase in total antibody levels in BAL fluids could be detected in intranasally immunized mice after aerosol challenge. Because of this observed variation in total antibody levels, specific anti-FHA titers in BAL fluids were not normalized to total antibody titers.
Limiting dilution analysis of lymphocytes isolated from the lungs and tracheas of intranasally immunized B6C3 mice demonstrated a 60-fold increase in FHA-specific B cells when compared to lymphocytes from unimmunized controls (Table 4) . However, no increase was observed in the frequency of FHA-specific splenic B lymphocytes from immunized mice when compared to unimmunized controls (Table  4) .
Gut immunization with FHA protects against respiratory B. pertussis infection. Since intranasal immunization was successful in eliciting protective immunity in the lung, we wished to determine if immunization of the gut with FHA could disseminate a protective immune response to the respiratory tract. Mice immunized with 100 ,g of FHA intraduodenally 3 weeks prior to aerosol challenge had approximately a 0.5 log reduction in bacterial recoveries from the lungs and tracheas compared to recoveries from unimmunized infected controls, although this reduction was not statistically significant (Table 5 ). Mice immunized with two intraduodenal doses of 100 ,g of FHA, given 1 week apart, and challenged 3 weeks after the last immunization showed a 2 log reduction in bacterial recoveries from the lungs (P < 0.01) and tracheas (P < 0.05) ( Table 5) . IgG anti-FHA was detected in both sera and BAL fluids after intraduodenal immunization; after aerosol challenge of immunized mice, IgA anti-FHA and IgG anti-FHA were detected in both sera and BAL fluids (Table 6 ).
DISCUSSION
We have demonstrated that mice immunized mucosally with purified FHA are protected against respiratory infection with B. pertussis. Adult mice immunized intranasally with FHA prior to aerosol challenge had a 2 to 3 log1o CFU decrease in bacterial recoveries from their lungs and tracheas in comparison to unimmunized controls (Table 1) . IgG anti-FHA was detected in the sera, and both IgG and IgA anti-FHA were detected in the BAL fluids of intranasally immunized mice on the day of aerosol challenge; specific serum antibodies to FHA further increased in titer 1 week after immunized mice had been infected with an aerosol ofB. pertussis (Table 2) . However, antibodies to FHA were not detected in unimmunized, infected animals at either 1 or 2 weeks after infection. Only antibodies specific for FHA were elicited by intranasal immunization with the preparations of FHA used in these experiments; therefore, the decreased infection observed after mucosal immunization with FHA was indeed due to immunity elicited by FHA and not to an immunogenic contaminant of the preparations of antigen used. Parenteral immunization with this same preparation of FHA prior to aerosol challenge also prevented leukocytosis and death in neonatal mice.
Kimura et al. previously demonstrated a 1 to 2 log decrease in bacterial recovery after parenteral immunization of adult mice with two 8-,ug doses of FHA (17 cific mucosal antibody in the upper respiratory tract of human subjects (20, 28, 40) . Thomas has shown that intramuscular immunization of adult human volunteers with killed whole pertussis vaccine caused increases in pertussis antibodies in sera but not in nasal secretions (41) . In contrast, deliberate intranasal immunization of subjects with an aerosol of the same vaccine resulted in pertussis antibodies in nasal secretions but not in sera. Our data demonstrate that intranasal immunization with a single purified protein of B. pertussis can protect against respiratory infection. Thus, respiratory immunization with pertussis antigens elicits specific protective immunity at the site of infection. In a randomized, placebo-controlled clinical trial of two parenteral pertussis vaccines, pertussis toxoid alone was highly effective in preventing severe clinical disease; however, the addition of FHA to pertussis toxoid appears to have provided some additional benefit in decreasing infection (38) . Of note is the observation that serum antibody titers to either antigen did not correlate with clinical protection in this trial (1) . Data from animal experiments suggest that the amount of specific antibody to pertussis antigens in the respiratory tract, resulting either from transudation from the serum (17, 37) or from local synthesis (Tables 2 and 4), correlates, in the case of FHA, with a decrease in B. pertussis infection. This hypothesis predicts, therefore, that antibodies to B. pertussis antigens in respiratory secretions, rather than in serum, may provide a correlate of vaccineinduced immunity to pertussis in humans.
A second advantage of local mucosal immunization is that this route may prime a population of antigen-specific B lymphocytes resident in the respiratory mucosal tissues that can be stimulated to differentiate and secrete protective antibody upon encountering the antigen associated with the whole bacterium during disease. This notion is supported by the observation of a 60-fold increase in the number of FHA-specific B lymphocytes isolated from the lungs of mice administered FHA intranasally, as determined by limiting dilution analysis (Table 4) .
Mice immunized via the gut with FHA also exhibited a decreased bacterial recovery, after aerosol challenge, with a significant reduction in bacterial recovery observed in mice receiving two intraduodenal doses of FHA (Table 5 ). FHA is extremely susceptible to proteolysis, and significant amounts of this antigen are likely degraded in the gut. Small but detectable amounts of IgA anti-FHA as well as IgG anti-FHA were detected in BAL fluids after gut immunization and aerosol challenge, but not after aerosol challenge alone, suggesting that intraduodenal immunization may also have resulted in a primed population of FHA-specific lymphocytes in the respiratory mucosa (Table 6) . Lymphocytes stimulated by antigen in the mucosal follicles of the gut can migrate via efferent lymphatics through the thoracic duct to the blood circulation; at the high endothelial venules, these circulating B lymphocytes can egress to seed distant mucosal tissues, including those of the respiratory tract (15, 44 (5) . Oral administration of vectors expressing pertussis antigens (24) or of whole killed B. pertussis cells (3) has been demonstrated to elicit specific antibody in mucosal secretions. We show here reproducible decreases in bacterial recoveries from the tracheas and the lungs of mice immunized either in the gut or intranasally with purified FHA in saline, in the absence of adjuvants known to enhance mucosal responses.
The follicle-associated epithelium is a highly endocytic cell layer overlying mucosal follicles, such as the bronchusassociated lymphoid tissue of the respiratory tract and the Peyer's patches of the gut, and serves as a mechanism of antigen delivery to the lymphocytes and antigen-presenting cells resident in the follicle. Antigens that can effectively bind to the follicle-associated epithelium have been shown to elicit mucosal antibody responses (7, 27, 29) . FHA, one of the major adhesins of B. pertussis, is a filamentous protein that contains a putative lectin-binding site (8) , as well as an arginine-lysine-aspartic acid (RGD) motif that mediates interactions with certain integrins (30 (Tables 2 and 5 ). IgG responses have been frequently reported after respiratory immunization (11, 22, 34, 43) and may reflect the transmission of antigen by lung macrophages through the lymphatics to the lymph nodes that drain the lung (16) as well as the transudation of IgG from the serum to the lung (37, 39) . Specific IgG antibody has been demonstrated in sera and BAL fluid washes in response to oral administration of Salmonella typhi Ty2la to humans (13) as well as in response to oral administration of microencapsulated antigen (10) to mice. Thus, the ability of an antigen to stimulate immunity at a mucosal site may reflect intrinsic properties of the antigen, such as size, shape, and charge of the molecule, as well as lectinlike qualities and receptor binding. All of these factors may affect the interaction with antigen-presenting cells and lymphoid cells, lymphokine release, and, ultimately, the characteristics of the immune response elicited.
Of interest was the observation that total IgG and IgA antibody titers increased in the BAL fluids of unimmunized, aerosol infected mice but not in intranasally immunized mice (Table 3) . At least one of the toxins associated with B. pertussis is known to increase capillary permeability (25) ; thus, this increase in total antibody in the lungs of unprotected animals may reflect leakage of total antibody from the serum into the lungs via the capillary beds. However, specific antibody to FHA, elicited by intranasal immunization prior to respiratory infection, may decrease the bacterial load in the respiratory tract, thus minimizing toxin release and capillary damage.
While the presence of specific IgG and IgA antibodies to FHA correlates with decreased bacterial recoveries in these experiments, it has not been established if protection is due to immune interference with bacterial colonization of the respiratory tract, killing of bacteria by opsonization and/or bactericidal antibody, or a combination of these mechanisms. In addition, antigen-specific T cells elicited by mucosal immunization with FHA may play a role in the observed protection against infection (9, 23) .
We have thus demonstrated that mucosal administration of one of the adhesins of B. pertussis is effective in decreasing infection, suggesting the feasibility of an oral pertussis vaccine designed to prevent infection. Current efforts are under way to formulate delivery vehicles for pertussis antigens to protect them from proteolysis and improve their delivery to the mucosal lymphoid follicles.
